MARKET

ERYP

ERYP

Erytech Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.50
+0.87
+10.06%
Closed 16:00 06/01 EDT
OPEN
8.82
PREV CLOSE
8.63
HIGH
9.79
LOW
8.82
VOLUME
2.11K
TURNOVER
--
52 WEEK HIGH
12.00
52 WEEK LOW
3.500
MARKET CAP
170.43M
P/E (TTM)
-2.4260
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ERYP stock price target is 17.75 with a high estimate of 22.32 and a low estimate of 13.19.

EPS

ERYP News

More
ERYTECH Announces Poster Presentations at ASCO 2020 Annual Meeting
ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announces the presentation of two posters at the American Society of Clini
GlobeNewswire · 1d ago
Erytech’s Combined Shareholders’ Meeting
Meeting held in closed session on June 26, 2020 Live webcast of the Shareholders’ Meeting Availability of the preparatory documents for the Shareholders’ Meeting LYON,.
GlobeNewswire · 6d ago
Monthly information related to total number of voting rights and shares composing the share capital – April 30, 2020
LYON, France, May 07, 2020 -- Article 223-16 of general regulation of French Autorité des Marchés FinanciersLyon – France Listing markets: Euronext Paris from Euronext.
GlobeNewswire · 05/07 16:00
The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs May 6.)
Benzinga · 05/07 11:42
ERYTECH Says Had Cash Position $64.6M At End Of Q1
Benzinga · 05/06 21:05
ERYTECH Provides Business Update and Reports Cash Balance at End of Q1 2020
ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today provided a business and financial update. “Our focus during the pas
GlobeNewswire · 05/06 20:30
ERYTECH engages in collaborative partnership with EU Horizon 2020 EVIDENCE consortium
ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, today announced it will be part of EVIDENCE, a public-private consortium supported by
GlobeNewswire · 05/05 20:30
Is ERYTECH Pharma (EPA:ERYP) Using Debt In A Risky Way?
Simply Wall St. · 05/05 07:41

Industry

Biotechnology & Medical Research
+0.07%
Pharmaceuticals & Medical Research
-0.77%

Hot Stocks

Symbol
Price
%Change

About ERYP

Erytech Pharma SA, also known as ERYTECH Pharma, is a France-based biopharmaceutical company developing medicinal products mainly in oncology, hematology and immunology fields of business. The Company offers ESY-ASP (GRASPA), a medicinal product consisting of L-Asparaginase entrapped into human homologous red blood cells. The product is used for treatment of Acute Lymphoblastic Leukemia (ALL), a childhood cancer. The Company's technology is based on the use of human red blood cells (RBCs) to improve the pharmacokinetic (PK) and pharmacodynamic (PD) properties of therapeutic enzymes, for instance asparaginase. The enzyme can destroy asparagine and deprive cancer cells of an important nutrient for these cells, resulting in their death. The Company's subsidiary is Erytech Pharma, Inc in the USA which legal existence began in April 9, 2014.
More

Webull offers kinds of Erytech Pharma SA (ADR) stock information, including NASDAQ:ERYP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ERYP stock news, and many more online research tools to help you make informed decisions.